Sagimet Biosciences Inc. 8-K

What Happened

• On March 11, 2026, Sagimet Biosciences, Inc. (SGMT) filed a Form 8-K reporting its results of operations and financial condition for the fourth quarter and year ended December 31, 2025. The company issued a press release with those results (attached as Exhibit 99.1 to the 8-K).
• The company also updated its investor slide presentation and disclosed it under Regulation FD; the revised presentation is attached as Exhibit 99.2 and will be used in meetings with investors going forward.

Key Details

• Filing date: March 11, 2026 (Form 8-K).
• Financial period covered: Q4 and full year ended December 31, 2025.
• Documents filed: Press release with financial results (Exhibit 99.1) and updated investor presentation (Exhibit 99.2).
• Disclosure type: Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD disclosure).

Why It Matters

• The press release contains the company’s most recent earnings and year‑end financial information — essential for assessing revenue, profitability, cash position, and recent operational trends. Investors should read Exhibit 99.1 for the specific numbers and any management commentary or guidance.
• The updated investor presentation reflects current corporate messaging and data the company will use in investor meetings; because it was disclosed under Regulation FD, all investors have equal access to the material. Review Exhibit 99.2 to understand how management is framing performance and upcoming priorities.